In 2 small trials of Japanese patients with SHPT on dialysis, evocalcet treatment reduced iPTH to target levels in a majority of patients within 30 to 32 weeks.
At 6 months after surgery, just 6.7% TPTx + AT had parathyroid hormone levels exceeding 200 pg/mL, compared with 38.9% of SPTx patients
In a small study, vitamin K antagonist use and liver dysfunction emerged as the most important factors in the development of calciphylaxis.
In an analysis of 2 randomized trials of patients with stage 3 to 4 chronic kidney disease, iPTH suppression did not occur until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL.
In a single center study, hungry bone syndrome developed in fewer patients on peritoneal dialysis than hemodialysis after parathyroidectomy.
In a study, patients with the highest preoperative levels of PTH tended to have higher postoperative levels than other transplant recipients.
Study supports the hypothesis that altered tubular phosphate handling drives the increase in serum phosphate during SGLT2 inhibition.
In a study, having the single nucleotide polymorphism rs11063112 in fibroblast growth factor 23 was associated with a 32% greater risk for cardiovascular mortality.